Sp188
PROGNOSTICATION OF DISEASE COURSE IN IBD: THE PRESENT AND THE FUTURE
Date
May 18, 2024
Explore related products in the following collection:
Presenter
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven
Tracks
Related Products
EFFICACY AND SAFETY OF OBEFAZIMOD IN UC PATIENTS AT WEEKS 48 AND 96 OF AN OPEN-LABEL MAINTENANCE STUDY AMONG CLINICAL RESPONDERS AT WEEK 8 OF THE PHASE 2B INDUCTION TRIAL
Obefazimod is an investigational, oral, once-daily, small molecule which enhances expression of microRNA-124 and is currently in phase 3 clinical trials for the treatment of patients with moderately to severely active ulcerative colitis (UC) [1]…
THE EFFECT OF NLRX1 ACTIVATION ON EOSINOPHILS IN ULCERATIVE COLITIS AND INFLAMMATION: TRANSLATIONAL LEARNINGS ACROSS DISEASES AND FROM MOUSE TO HUMAN
Background: Although the precise role of eosinophils in IBD is debated, elevated eosinophils may influence response to therapy and clinical outcomes1. Thus, therapeutic agents which affect both neutrophil and eosinophil recruitment may provide more robust clinical improvement in patients with UC…
SAFETY AND EFFICACY OF MH002, AN OPTIMIZED LIVE BIOTHERAPEUTIC PRODUCT, FOR THE TREATMENT OF MILD TO MODERATE ULCERATIVE COLITIS: A FIRST-IN-DISEASE, DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL
BACKGROUND: Treatment options for patients with mild to moderate ulcerative colitis (UC) failing 5ASA are limited. MH002 is an optimized consortium of 6 nonpathogenic, well characterized commensal bacteria with immunomodulating, wound healing and gut barrier protective effects…
ENDOSCOPIC OUTCOMES WITH EARLY TREATMENT IN NEWLY-DIAGNOSED CROHN’S DISEASE: EVIDENCE FROM PROFILE, A MULTI-CENTRE, RANDOMIZED, OPEN-LABEL, BIOMARKER-STRATIFIED CLINICAL TRIAL
Management strategies and clinical outcomes vary substantially in patients newly-diagnosed with Crohn’s disease…
